Understanding the True Costs of “Cheap” LFA Development
In this episode of DCN Dx’s Expert Insights, Mitzi Rettinger interviews Dr. Pat Vaughan, COO of DCN Dx, to explore the risks of working with inexperienced or low-cost lateral flow assay developers. While these options may seem cost-effective at first glance, they often lead to costly delays, redesigns, or outright project failures. Drawing from real-world case studies, Dr. Vaughan shares insights on how experience and technical expertise can help mitigate risks and ensure successful assay development and commercialization.
Why Listen?
This episode dives into the key considerations for selecting an LFA development organization, with a focus on identifying and avoiding the pitfalls of working with inexperienced providers. You’ll gain insights into:
- Real-world case studies where DCN Dx turned around failing projects to deliver successful, market-ready products.
- The long-term risks and hidden costs of partnering with cheap lateral flow developers.
- Key qualities to look for in a development partner, including manufacturability, scalability, and regulatory readiness.
- Specific guidance in how to evaluate RFP responses from prospective LFA development partners.
- Gain access to our free, downloadable rubric to evaluate potential lateral flow assay development partners and ensure your project stays on track—click here to get started.
Expert Panelists
Mitzi Rettinger, Chief Revenue Officer at DCN Dx; Show Host
Mitzi Rettinger, Chief Revenue Officer at DCN Dx, is a dynamic force in the life sciences industry, with more than 25 years of experience fueling innovation and growth across various sectors, including diagnostics, pharmaceuticals, and biotechnology. Her expertise lies in driving sustainable revenue growth, market development, and digital transformation, leveraging her deep understanding of the scientific commercial landscape.
Pat Vaughan, Ph.D., Chief Operating Officer at DCN Dx
Dr. Pat Vaughan oversees DCN Dx’s IVD CDMO and CRO services, guiding complex projects from early feasibility through full-scale manufacturing. With over two decades of experience across multiple diagnostic platforms—including lateral flow, molecular diagnostics, and point-of-care devices—Dr. Vaughan’s team at DCN Dx specializes in ensuring products are manufacturable, scalable, and regulatory-ready.
